Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Van Dyck

Psychiatry Raleigh, NC Medical Doctor

NPI 1730275470 CMS profile 78915

4601 Lake Boone Trl Ste 1B, Raleigh, NC 27607

Open in the dashboard

General payments

$2,746

140 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Van Dyck of Raleigh, NC is reported in the CMS Open Payments database as having received $2,746 across 140 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $309 16
2024 General $539 23
2023 General $100 6
2020 General $295 12
2019 General $1,503 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Van Dyck
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Peter Van Dyck were reported at $309. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Peter Van Dyck Psychiatry median Middle half National median
2019 $1,503 $184 $59–$605 $163
2020 $295 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $100 $170 $56–$651 $160
2024 $539 $179 $57–$673 $164
2025 $309 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sunovion Pharmaceuticals Inc. $402 14 payments
  2. Allergan Inc. $333 23 payments
  3. Janssen Pharmaceuticals, Inc $231 7 payments
  4. Otsuka America Pharmaceutical, Inc. $222 11 payments
  5. Neos Therapeutics, LP $211 13 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $152 11 payments
  7. Axsome Therapeutics, Inc. $143 6 payments
  8. Ironshore Pharmaceuticals Inc. $127 6 payments
  9. Bausch Health US, LLC $100 5 payments
  10. Neurocrine Biosciences, Inc. $90 5 payments
  11. Other $734 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,567 135 payments
  2. Education $179 5 payments
Products named General payments · program years 2019–2025
  1. LATUDA $396 13 payments
  2. VRAYLAR $362 24 payments
  3. REXULTI $222 11 payments
  4. SPRAVATO $156 3 payments
  5. Adzenys XR-ODT $145 9 payments
  6. COTEMPLA XR-ODT $145 9 payments
  7. Auvelity $143 6 payments
  8. Jornay PM 20mg capsules (Bottle of 100) $103 5 payments
  9. APLENZIN $100 5 payments
  10. VYVANSE $85 6 payments
  11. Other $1,328 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

3,011

Median for Psychiatry & Neurology: 100

Drug cost

$195,507

Median for Psychiatry & Neurology: $2,986

Branded share of claims

21.9%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 12 $95,396
Vraylar Cariprazine Hcl Brand 17 $32,657
Trintellix Vortioxetine Hydrobromide Brand 15 $13,885
Concerta Methylphenidate Hcl Brand 11 $5,178
Bupropion Xl Bupropion Hcl Brand 163 $3,399
Carbamazepine Er Carbamazepine Brand 40 $3,123
Quetiapine Fumarate Generic 185 $3,089
Divalproex Sodium Er Divalproex Sodium Brand 41 $2,369
Gabapentin Generic 143 $2,363
Fluoxetine Hcl Generic 132 $2,290

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $97
$97 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $78
$78 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $40
  • Lundbeck LLC $15
$55 — —
LOREEV XR
  • Almatica Pharma LLC $44
$44 — —
Adzenys XR-ODT
  • Neos Therapeutics, LP $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record